This article serves as a formal correction to the research paper "Discovery of novel 4-trifluoromethyl-2-anilinoquinoline derivatives as potential anti-cancer agents targeting SGK1," originally published in the journal Molecular Diversity. The correction addresses critical typographical errors in the graphical abstract that misrepresented the potency of the study's lead compound.
The Core Correction: Potency and Units
The primary purpose of this notice is to rectify the reporting of $IC_{50}$ values for the lead anti-cancer compound, 8b. In the original publication, the graphical abstract erroneously listed the inhibitory concentrations in millimolar (mM) units. In medicinal chemistry, this distinction is vital; a millimolar concentration suggests a compound with negligible therapeutic potential, whereas a micromolar ($\mu$M) concentration indicates significant biological activity.
The corrected data confirms that compound 8b exhibits micromolar potency, making it a 1,000-fold more effective inhibitor of cancer cell growth than initially suggested. Additionally, the specific $IC_{50}$ value for the LNCaP cell line was corrected from 1.59 to 1.89.
Methodology and Structural Design
The research focused on developing inhibitors for Serum/Glucocorticoid Regulated Kinase 1 (SGK1), a protein often overexpressed in various cancers that contributes to tumor survival and therapy resistance. The authors utilized a systematic medicinal chemistry approach to optimize their lead scaffold:
- Metabolic Site Blocking: A trifluoromethyl ($-CF_3$) group was introduced at the 4-position of the quinoline ring to block potential metabolic sites, potentially enhancing the molecule's stability in vivo.
- Pharmacophore Hybridization: The researchers created a hybrid scaffold by combining 2-anilinoquinoline with the $-CF_3$ group.
- Structural Optimization: Iterative synthesis and "enrichment" of the compound structure led to the identification of compound 8b, which features a methoxy group and a piperazine moiety.
Biological Evaluation Results
The corrected biological data for compound 8b across four human cancer cell lines are as follows:
- PC3 (Prostate): $IC_{50} = 1.13\text{ }\mu\text{M}$
- LNCaP (Prostate, androgen-sensitive): $IC_{50} = 1.89\text{ }\mu\text{M}$
- K562 (Chronic Myelogenous Leukemia): $IC_{50} = 3.45\text{ }\mu\text{M}$
- HeLa (Cervical): $IC_{50} = 3.14\text{ }\mu\text{M}$
Compound 8b also demonstrated a Selectivity Index (SI) of 12.57, indicating a favorable therapeutic window between its anti-cancer effects and potential toxicity to non-cancerous cells.
Conclusion
This correction ensures the accuracy of the scientific record regarding the development of 4-trifluoromethyl-2-anilinoquinoline derivatives. By clarifying the micromolar potency of compound 8b, the authors reaffirm its potential as a viable candidate for further development as an SGK1-targeted anti-cancer agent.
Summary updated